Total Funding
74
60
Total FundingSeries A raised
Growth Score
-9 pts
Heat Score
-2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
42382
AbolerIS Pharma develops immuno-modulators as treatments for transplant rejection, graft-versus-host disease, and auto-immune diseases.
- Ann Meulemans: CEO
- Carole Guillonneau: Co-founder
About the Company
AbolerIS Pharma has a novel and distinct therapeutic approach that induces immune tolerance and preserves useful immune responses in inflammatory, autoimmune, and degenerative diseases, allowing researchers to concentrate on the development of novel drugs in areas of unmet medical need.
